• $211.8M
    Market Cap
  • -68.90%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
0
N/A
0
N/A
0
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
957,670
0.00%
957,670
N/A
N/A
N/A
3.0M
N/A
Research and Development Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
76,398
-20.25%
95,792
+47.75%
64,833
-97.96%
3.2M
+21,540.26%
Operating Profit
-76,398
-20.25%
-95,792
+47.75%
-64,833
-97.96%
-3.2M
+21,540.26%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Income before Taxes
-76,398
-20.25%
-95,792
+47.75%
-64,833
-97.96%
-3.2M
+21,540.26%
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-76,398
-20.25%
-95,792
+47.75%
-64,833
-97.96%
-3.2M
+21,540.26%
Net Income from Continuing Operations Applicable to Common
-76,398
-20.25%
-95,792
+47.75%
-64,833
-97.96%
-3.2M
+21,540.26%
Basic EPS and Net Income
0.00
N/A
0.00
N/A
0.00
N/A
0.00
N/A
Diluted EPS and Net Income
0.00
N/A
0.00
N/A
0.00
N/A
0.00
N/A
Basic Weighted Average Shares
1.0B
+2.53%
1.0B
+16.62%
876.1M
+21.01%
724.0M
+5,383.25%
Diluted Weighted Average Shares
1.0B
+2.53%
1.0B
+16.62%
876.1M
+21.01%
724.0M
+5,383.25%
Balance Sheet
Cash and Cash Equivalents
1,889
-9.31%
2,083
-89.37%
19,596
+2,168.06%
864
+116.54%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
1,889
-9.31%
2,083
-89.37%
19,596
+2,168.06%
864
+116.54%
Total Current Assets
20,996
+17.07%
17,934
-8.48%
19,596
+2,168.06%
864
+116.54%
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Assets
20,996
+17.07%
17,934
-8.48%
19,596
+2,168.06%
864
+116.54%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
318,624
+33.22%
239,164
+135.06%
101,745
+459.65%
18,180
+72.85%
Total Current Liabilities
318,624
+33.22%
239,164
+135.06%
101,745
+459.65%
18,180
+72.85%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
318,624
+33.22%
239,164
+135.06%
101,745
+459.65%
18,180
-24.31%
Retained Earnings
-9.0M
+0.86%
-8.9M
+162.56%
-3.4M
-201.94%
3.3M
+2,098.71%
Total Stockholders Equity
-297,628
+34.53%
-221,230
+169.30%
-82,149
+374.41%
-17,316
-26.69%
Total Shares Outstanding
1.0B
+2.06%
1.0B
+17.15%
876.1M
0.00%
876.1M
+6,535.54%
Cash Flow
Cash from Operating Activities
-79,654
-42.73%
-139,081
-314.52%
64,833
+92.30%
33,715
+329.17%
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
79,460
-42.18%
137,419
+64.45%
83,565
+144.49%
34,180
+153.19%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-392.49%
-23.11%
-510.48%
-19.45%
-633.75%
-99.87%
-504,151.23%
+34,339.37%
Return on Equity
29.45%
-53.37%
63.15%
-51.56%
130.36%
-99.16%
15,554.98%
+17,094.85%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
0.07
-12.13%
0.08
-61.06%
0.19
+305.47%
0.05
+25.33%
Cash Ratio
0.006
-32.18%
0.009
-95.48%
0.19
+305.47%
0.05
+25.33%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow